SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 182,807 shares, a drop of 19.1% from the February 12th total of 226,049 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 90,033 shares, the days-to-cover ratio is currently 2.0 days. Based on an average daily trading volume, of 90,033 shares, the days-to-cover ratio is currently 2.0 days. Currently, 0.3% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Guggenheim upped their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Price Performance

SOPH stock opened at $4.91 on Tuesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The business has a 50-day simple moving average of $4.88 and a two-hundred day simple moving average of $4.50. The company has a market capitalization of $336.29 million, a P/E ratio of -9.63 and a beta of 1.13. SOPHiA GENETICS has a 52-week low of $2.58 and a 52-week high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million during the quarter, compared to analysts’ expectations of $21.20 million. Research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in SOPHiA GENETICS in the 2nd quarter worth about $775,000. Archon Capital Management LLC purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at about $997,000. Federated Hermes Inc. increased its stake in SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after buying an additional 31,000 shares during the last quarter. Finally, Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.